John Quisel News Today

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

DISC-0974 is an investigational monoclonal antibody against hemojuvelin, a bone morphogenetic protein-signaling co-receptor.

The FDA has granted Fast Track designation to DISC-0974 for the treatment of anemia in patients with NDD-CKD.

DISC-0974 is an investigational monoclonal antibody against hemojuvelin, a bone morphogenetic protein-signaling co-receptor.

WATERTOWN, Mass., Feb. 20, 2024 -- Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients...

By Dean Seal Disc Medicine said regulators have granted orphan drug designation for DISC-3405, its treatment for patients with the rare blood disorder...

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from

WATERTOWN, Mass., Jan. 03, 2024 -- Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients...

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel